HD Project: Neurodegenerative Disease Research Platform - Novel Remote Monitoring and Deep Phenotyping.

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This observational study aims to identify novel biomarkers of disease onset and progression in Huntington's disease by integrating remote monitoring with fluid biomarkers. Using video-based computer vision and mobile app-based cognitive assessments combined with machine learning algorithms, we aim to develop markers that can be used by Huntington's disease patients at home. Using machine learning to analyze videos of movement will capture the movements with an accuracy that will be as good as seeing an expert neurologist. These individualized markers can be followed over time to evaluate symptoms onset and change. The study will track disease progression and correlate these digital markers with changes in plasma and cerebrospinal fluid. The ultimate goal is to advance biomarker discovery and therapeutic development for Huntington's disease. The study includes one in-person visit per year. A remote visit via Zoom or Facetime (15 min) every three months to record videos of movement. We can also share cutting-edge wristbands and a mobile phone app.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Individuals with a positive test for the HD expansion mutation.

Locations
United States
California
Stanford University
RECRUITING
Palo Alto
Contact Information
Primary
Minhtrang Chu, Study Coordinator
mtchu@stanford.edu
650-250-3160
Backup
Olivia Lu, Study Coordinator
olivialu@stanford.edu
650-374-9286
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2035-12
Participants
Target number of participants: 200
Treatments
Huntington's disease
Individuals who carry the Huntington's disease mutation. Individuals with pre-manifest or manifest disease at all disease stages are welcome
Sponsors
Collaborators: Schwab Charitable Fund
Leads: Stanford University

This content was sourced from clinicaltrials.gov